Showing results filtered by:
July 25, 2019

Advances in HIV treatment options and studies on HIV prevention for women and girls were among the highlights yesterday at the 10th International AIDS Society Conference on HIV Science (IAS 2019). On the third and final day of the conference, NIAID's Carl Dieffenbach, Ph.D., and Anne Rancourt joined for a Facebook Live session to discuss those studies, reflect on key meeting takeaways, and look ahead to research developments on the horizon.

July 24, 2019

HIV prevention research was in the spotlight yesterday at the second full day of presentations at the 10th International AIDS Society Conference on HIV Science (IAS 2019). NIAID's Carl Dieffenbach, Ph.D., and Anne Rancourt joined for a Facebook Live session to discuss research about an experimental implantable form of PrEP and other findings that inform HIV prevention and treatment interventions.

July 23, 2019

As the 10th International AIDS Society Conference on HIV Science, or IAS 2019, opened in Mexico City, hosted a Facebook Live session with NIAID's Carl Dieffenbach, Ph.D., about initial research presented there and what is in store. Dr. Dieffenbach spoke with his colleague Anne Rancourt. They previewed a topic to be discussed at the conference: what’s new in the HIV prevention landscape, including HIV vaccine research. They also discussed new findings presented on Monday about a potential association between the HIV treatment medication dolutegravir and birth defects.

July 23, 2019

How to end the HIV epidemic is a theme of many conversations and presentations at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. After delivering presentations on that topic, NIAID Director Dr. Anthony Fauci shared his thoughts with He observed that we now have the HIV prevention and treatment tools that, if implemented properly and aggressively, could theoretically end the HIV epidemic. He also acknowledged that implementation is a key issue and that there is a need for continued innovation and research.

June 26, 2019

When countries began providing HIV treatment to all people diagnosed with the virus, regardless of their immune health, the proportion of people who started treatment within a month of enrolling in HIV care jumped sharply in some nations, a study has found.

June 5, 2019

As NHLBI, NIAID, the Office of AIDS Research, and other NIH components adapt to the changing epidemiology of HIV infection, we are working together to support a coordinated research agenda that will optimize the health of people with HIV and improve their quality of life by reducing HIV-related co-morbidities. This year, on HIV Long-Term Survivors Day, we renew our commitment to study HIV disease across the lifespan.

May 29, 2019

Researchers launched the Randomized Trial to Prevent Vascular Events in HIV, or REPRIEVE, in 2015 with support from NIAID and the National Heart, Lung and Blood Institute. The ambitious trial is testing the ability of a statin medication to reduce the risk of heart disease in men and women with HIV. Researchers completed the enrollment phase of the trial earlier this year, welcoming more than 7,500 participants in eleven countries. REPRIEVE investigators and NIAID collaborators discussed the design and goals of the trial in the June issue of the American Heart Journal.

May 22, 2019

At the National Institute of Allergy and Infectious Diseases, we are proud of our legacy in HIV research, and we look for every opportunity to strengthen the ways we and our partners conduct clinical research and ensure that the trials we sponsor meet our regulatory responsibilities. Last year, the NIAID Division of AIDS initiated a mock inspection to evaluate the processes and systems associated with our clinical trial operations.

May 13, 2019

The National Institute of General Medical Sciences (NIGMS) has a rich history of fostering fundamental HIV research. Recently, NIGMS leadership had the strategic insight that this portfolio should be combined with the existing basic research program at NIAID to maximize collaboration and better leverage existing resources. NIGMS has excelled in fostering this research for 37 years, and we are honored to welcome their researchers into our scientific community.

March 6, 2019

Even when HIV is well-controlled with antiretroviral therapy, the virus can cause persistent immune activation that contributes to an increased risk of complications such as heart disease and certain cancers. New NIAID-supported research presented today at CROI 2019 in Seattle sheds light on the relationship between immune activation and weight gain.

March 6, 2019

As the first full day of presentations at the 2019 Conference on Retroviruses and Opportunistic Infections began to wrap up, spoke with NIAID's Dr. Carl Dieffenbach about some of the new HIV research highlights presented, including the case of a patient reported to be possibly cured of HIV infection. They also discussed the promising findings from a large study evaluating a “universal test and treat” strategy, as well as other results showing improved viral suppression and retention in care when point-of-care viral load testing is offered.

March 5, 2019

Rarely, people living with HIV are unable to maintain an undetectable viral load despite strict adherence to antiretroviral therapy (ART). NIAID-funded research suggests that this sometimes can occur when a single cell from the HIV reservoir—the population of long-lived HIV-infected cells that ART cannot eradicate—multiplies to create many identical cells that produce enough virus to be detected by standard viral load tests.

March 5, 2019 kicked off coverage of the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) with an interview with NIAID's Dr. Carl Dieffenbach just hours before the conference opened in Seattle. Dr. Dieffenbach spoke with his colleague Anne Rancourt about some of the current issues in the field of HIV research as well as what he is looking forward to learning more about at this year’s conference of HIV researchers from around the globe.

March 5, 2019

NIAID Director Anthony S. Fauci, M.D., addressed the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) last night about Ending the HIV Epidemic: A Plan for America and the role HIV research will play in it. spoke with Dr. Fauci ahead of his remarks at the opening plenary session of the conference.

January 29, 2019

In observance of World AIDS Day, HIV experts discussed the future of the epidemic with community members at the Smithsonian’s National Museum of Natural History in Washington, D.C. Co-hosted by the American Society for Microbiology, “Imagining an HIV-Free Future” was one in a series of programs related to the new exhibition, Outbreak: Epidemics in a Connected World.

January 23, 2019

The safety and dosing requirements of a new drug licensed for use by nonpregnant adults may differ for pregnant women. This has been the case for drugs for treating both HIV and tuberculosis (TB), the most common HIV co-infection. An NIH study into how pregnancy affects the body’s processing of drugs for HIV and TB has helped provide a foundation for national and international HIV treatment guidelines for women who are pregnant or have recently given birth.

January 17, 2019

HIV is a master of sneaking past our natural defenses. Typically, when the body encounters a harmful virus, immune cells recognize viral proteins and stimulate the production of antibodies. HIV, however, has evolved several ways to cloak vulnerable areas of viral proteins. A report released last month from NIAID scientists reveals new insights into one such tactic of immune invisibility.

January 7, 2019

Scientists have previously recognized that the HIV reservoir varies in size between individuals. Now, NIAID researchers and their collaborators have discovered that variations in an important viral gene may play a role in the size of one’s HIV reservoir. Their findings, reported online last week, expand scientists’ understanding of how specific attributes of the virus a person acquires can affect the course and nature of their HIV infection.

January 3, 2019

NIAID’s HIV/AIDS Flickr album features a collection of downloadable HIV-related images, including infographics, microscopy images, photographs of HIV researchers and molecular models. These images are public domain and can be freely re-used. Please credit the National Institute of Allergy and Infectious Diseases.

October 25, 2018

At this week's HIV Research for Prevention (HIV R4P) conference in Madrid, scientists have reported progress in numerous areas of HIV prevention research. NIAID-supported scientists highlighted the need to expand HIV prevention and treatment services among populations greatly affected by HIV, described early findings from a study assessing the safety of a vaginal ring containing both an anti-HIV drug and a birth-control agent, and reported the added benefits of an intervention designed to facilitate treatment for HIV and injection drug use.

October 23, 2018

A durable end to the HIV/AIDS pandemic will require the development and widespread implementation of new and improved HIV prevention tools, according to NIAID Director Anthony S. Fauci, M.D. Yesterday, Dr. Fauci delivered a plenary lecture at the opening session of the HIV Research for Prevention (HIV R4P) conference, which is taking place this week in Madrid.

September 13, 2018

Some people treated with antiretroviral therapy after HIV has already significantly damaged the immune system may develop a serious condition called HIV-associated immune reconstitution syndrome, or IRIS. Now, researchers from NIAID and the NIH Clinical Center are working together to visualize and predict this common complication of HIV in a new way—with positron emission tomography, or PET.

July 30, 2018

The gut microbiome—the community of bacteria and other microbes naturally present in the gastrointestinal tract—plays a critical role in human health. NIAID Now spoke with senior investigator Jason Brenchley, Ph.D., about the link between the gut microbiome and HIV infection, and his lab’s recent research findings.

July 27, 2018 wrapped up their series of conversations with NIAID's Carl Dieffenbach, Ph.D., about scientific highlights from the 22nd International AIDS Conference (AIDS 2018) as the conference began to wind down.

July 25, 2018

As part of's series of Facebook Live dispatches from the 22nd International AIDS Conference in Amsterdam, Carl Dieffenbach, Ph.D., shared highlights from the conference's second full day of HIV research presentations.

July 24, 2018

As the 22nd International AIDS Conference (AIDS 2018) got underway in Amsterdam, began coverage of HIV research advances and other conference highlights with a Facebook Live interview with NIAID Director Anthony S. Fauci, M.D.

July 24, 2018

The first full day of sessions at the 22nd International AIDS Conference  (AIDS 2018) in Amsterdam was filled with new scientific findings shared by researchers from around the world. In a Facebook Live interview with, Carl Dieffenbach, Ph.D., discussed highlights of three studies presented today at the conference.

July 22, 2018

People living with HIV whose virus is completely, durably suppressed by treatment will not sexually transmit the virus to an HIV-negative partner, according to NIAID Director Anthony S. Fauci, M.D. The success of this HIV prevention strategy is contingent on achieving and maintaining an undetectable viral load by taking HIV medication daily as directed. Dr. Fauci delivered these remarks at the "U=U 2018: Celebrate, Activate and Implement!" meeting held prior to AIDS 2018.

July 6, 2018

Why do we lack a cure for HIV infection, and what research is underway to help achieve that goal? A new video from NIAID provides answers.

June 21, 2018

A clinical trial comparing three chemotherapy regimens in combination with antiretroviral treatment for treatment of advanced AIDS-Kaposi’s sarcoma patients in Africa and South America has ended early.

June 15, 2018

The Broadway and Hollywood star, a lifelong advocate of health and gender equity, graced the stage of NIH’s Ruth Kirschstein Auditorium on May 15 to give the annual J. Edward Rall Cultural Lecture, named for former Deputy Director for Intramural Research Joseph “Ed” Rall. Streisand took the opportunity to highlight an issue that is — literally — near and dear to her heart: women’s cardiovascular health.

May 3, 2018

HIV-related heart disease is a leading cause of death among people living with HIV—even when they are on consistent, effective HIV treatment. Researchers are learning that this complication is likely brought on by chronic inflammation from the virus itself and other factors. What is less understood is why HIV seems to take a greater toll on the hearts of women.

March 22, 2018

Most people living with HIV have a single genetic strain of the virus, but in certain cases, a person can acquire a second strain of HIV—a condition known as HIV superinfection. In a new study published online today in the Journal of Infectious Diseases, NIAID researchers and scientists at the Uganda Virus Research Institute describe a case of HIV superinfection they were able to identify with unique precision.

March 8, 2018

Our coverage from the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston wrapped up yesterday with two interviews with Federal HIV leaders who shared perspectives about the science coming out of the conference and its implications for HIV prevention, care, and treatment.

March 7, 2018

During the second full day at the Conference on Retroviruses and Opportunistic Infections in Boston, NIAID’s Anne Rancourt conducted Facebook Live interviews with three leaders from the Department of Health and Human Services about HIV research highlights and their implications.

March 6, 2018

Advances in HIV research are being shared this week at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. conducted a Facebook Live interview with NIAID’s Dr. Carl Dieffenbach on Monday afternoon to learn about some of the key research findings presented during the first full day of sessions.

March 4, 2018

A woman’s risk of acquiring HIV through sex with a male partner living with HIV increases during pregnancy and is highest during the postpartum period, new research funded in part by NIAID suggests. Researchers observed this trend of increased risk of HIV transmission per sex act even after taking into account behavioral factors, such as use of condoms or PrEP. The findings suggest that biological changes during and after pregnancy may increase a woman’s HIV risk.

February 20, 2018

NIAID scientists have demonstrated that a slight change to a powerful, naturally occurring HIV antibody helps it last longer in the human body while counteracting the virus just as well in the laboratory. These characteristics could reduce the cost and increase the convenience of giving people antibodies for HIV prevention because fewer doses of an antibody could achieve the same protective effect.

February 14, 2018

Today marks not just a time to exchange valentines and chocolates, but also the midpoint of American Heart Month. Did you know people living with HIV are at an increased risk of experiencing cardiovascular disease? Fortunately, NIH-supported research is getting to the heart of the problem.

January 16, 2018

NIAID makes many resources available to researchers, such as reagents, model organisms, and tissue samples. Now it’s even easier to find these resources on our site using the Resources for Researchers feature.

November 28, 2017

To make additional HIV prevention options a reality, NIAID supports research on a variety of innovative, long-acting HIV prevention products that could be inserted in the vagina, injected or implanted from once a month to once a year by people who commit to use them on an ongoing basis. These products include a vaginal ring that also delivers contraception.

November 21, 2017

NIH-funded researchers are developing and testing HIV prevention products that may become alternatives to a daily pill.

November 14, 2017

Daily antiretroviral therapy can reduce the amount of HIV in the blood to levels that are undetectable with standard tests. Staying on treatment is crucial to keep the virus suppressed. NIAID-supported research has demonstrated that achieving and maintaining a “durably undetectable” viral load (the amount of HIV in the blood) not only preserves the health of the person living with HIV, but also prevents sexual transmission of the virus to an HIV-negative partner.

October 4, 2017

A short animation explains how HIV hijacks the cellular protein alpha-4 beta-7 to home to the gut and establish infection in this organ system, which harbors one of the richest populations of HIV target cells in the body.

September 18, 2017

Today marks the 10th National HIV/AIDS and Aging Awareness Day. This annual observance brings attention to the unique social and health-related challenges of older people living with and at risk for HIV. NIAID supports and collaborates on research that aims to both understand and mitigate long-term complications of HIV for men and women aging with HIV.

July 21, 2017

Ensuring a durable end to the HIV pandemic will require a safe and effective HIV vaccine. A whiteboard video explains how an HIV vaccine could be developed, while focusing on a vaccine currently being tested in a large, NIAID-funded clinical trial in South Africa called HVTN 702.